Progress in developing cationic vectors for non-viral systemic gene therapy against cancer

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Gene therapy's scope has expanded beyond hereditary conditions to acquired diseases like cancer.
• Advances in understanding cancer's molecular mechanisms and nucleic acid delivery systems drive this evolution.
• Systemic gene delivery is crucial for reaching inaccessible tumor cells and metastatic sites.

Purpose of the Study:

• To review existing gene therapy vectors for cancer treatment.
• To identify challenges and limitations of current non-viral vectors.
• To define the characteristics of an ideal vector for systemic cancer gene therapy.

Main Methods:

• Review of current literature on gene therapy vectors for cancer.
• Analysis of safety and efficacy data for viral and non-viral vectors.
• Comparative assessment of cationic lipids and polymers as non-viral delivery systems.

Main Results:

• Viral vectors present safety concerns for therapeutic applications.
• Non-viral vectors, including cationic lipids and polymers, offer a safer alternative.
• Achieving transfection efficiency comparable to viral vectors remains a key challenge for non-viral systems.

Conclusions:

• Non-viral vectors are promising for systemic cancer gene therapy.
• Further development is needed to overcome transfection efficiency limitations.
• The "perfect vector" for cancer gene therapy requires balancing safety, efficacy, and targeted delivery.